Caredx Inc CDNA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$64.00 down $2.68, 4.01% at close Oct 16
Last close · Previous close $66.68
- Market cap
- At the Oct 16 close
- P/E ratio
- 30.92On last 12 months’ EPS
- Diluted EPS
- $2.07Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$64.00down $2.68, 4.01%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$66.68Oct 15
- Volume1.50MOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.56MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $14.03 to $72.51; now $64.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CDNA beat the S&P 500 in 6 of 7 periods.
| Period | CDNA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CDNA: up 19.5% S&P 500: up 1.5% | CDNA beat the S&P 500 by 18.0 percentage points Beat |
| 3M | CDNA: up 58.7% S&P 500: up 1.9% | CDNA beat the S&P 500 by 56.8 percentage points Beat |
| YTD | CDNA: up 239.7% S&P 500: up 12.8% | CDNA beat the S&P 500 by 226.9 percentage points Beat |
| 1Y | CDNA: up 327.0% S&P 500: up 16.8% | CDNA beat the S&P 500 by 310.2 percentage points Beat |
| Long term | ||
| 3Y | CDNA: up 1,009.2% S&P 500: up 81.5% +123.0% vs +22.0% a year | CDNA beat the S&P 500 by 927.7 percentage points Beat |
| 5Y | CDNA: down 9.9% S&P 500: up 83.1% −2.1% vs +12.9% a year | CDNA trailed the S&P 500 by 93.0 percentage points Trailed |
| 10Y | CDNA: up 1,629.7% S&P 500: up 319.6% +33.0% vs +15.4% a year | CDNA beat the S&P 500 by 1,310.1 percentage points Beat |
$10,000 invested in CDNA 10 years ago (Oct 14, 2016) would be worth about $172,973 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
CDNA beat the S&P 500 in 6 of 7 periods.
| Period | CDNA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CDNA: up 19.5% S&P 500: up 1.2% | CDNA beat the S&P 500 by 18.3 percentage points Beat |
| 3M | CDNA: up 58.7% S&P 500: up 1.7% | CDNA beat the S&P 500 by 57.0 percentage points Beat |
| YTD | CDNA: up 239.7% S&P 500: up 11.9% | CDNA beat the S&P 500 by 227.8 percentage points Beat |
| 1Y | CDNA: up 327.0% S&P 500: up 15.5% | CDNA beat the S&P 500 by 311.5 percentage points Beat |
| Long term | ||
| 3Y | CDNA: up 1,009.2% S&P 500: up 75.0% +123.0% vs +20.5% a year | CDNA beat the S&P 500 by 934.2 percentage points Beat |
| 5Y | CDNA: down 9.9% S&P 500: up 71.2% −2.1% vs +11.4% a year | CDNA trailed the S&P 500 by 81.1 percentage points Trailed |
| 10Y | CDNA: up 1,629.7% S&P 500: up 258.1% +33.0% vs +13.6% a year | CDNA beat the S&P 500 by 1,371.6 percentage points Beat |
$10,000 invested in CDNA 10 years ago (Oct 14, 2016) would be worth about $172,973 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$95.60
Closing high on . Now 33.1% below that record.
Split-adjusted daily closes since Jul 17, 2014.
Stock splits
CDNA hasn’t split since its price history begins in 2014.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $458.09Mup 34.4%
- Net income
- $111.01Mup 90.9%
- Diluted EPS
- $2.07up 97.1%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $82.88M | −$10.64M | −$0.20 |
| Q4 FY24 (Dec 31, 2024) | $86.58M | $87.70M | $1.60 |
| Q1 FY25 (Mar 31, 2025) | $84.69M | −$10.35M | −$0.19 |
| Q2 FY25 (Jun 30, 2025) | $86.68M | −$8.57M | −$0.16 |
| Q3 FY25 (Sep 30, 2025) | $100.06M | $1.68M | $0.03 |
| Q4 FY25 (Dec 31, 2025) | $108.39M | −$4.11M | −$0.08 |
| Q1 FY26 (Mar 31, 2026) | $117.70M | $2.81M | $0.05 |
| Q2 FY26 (Jun 30, 2026) | $131.95M | $110.64M | $2.07 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $296.40M | −$30.66M | −$0.59 |
| FY22 (Dec 31, 2022) | $321.79M | −$76.61M | −$1.44 |
| FY23 (Dec 31, 2023) | $280.32M | −$190.28M | −$3.54 |
| FY24 (Dec 31, 2024) | $333.79M | $52.55M | $0.93 |
| FY25 (Dec 31, 2025) | $379.81M | −$21.35M | −$0.40 |
Margins
- Gross 70.6%
- Operating 23.6%
- Net 24.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $84.71MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$93.66MLast 12 months
- Capital spending$8.95MLast 12 months
- 18.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $44.50MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$44.50MLast 12 months
53% of free cash flow
Balance sheet
- $374.16MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$13.20MAs of Jun 30, 2026
- Net cash$360.96MAs of Jun 30, 2026
- 4.58As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.03As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 8 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 32.8%Last 12 months
Over the last 12 months, Caredx’s net income was 32.8% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 24.8%Last 12 months
Over the last 12 months, Caredx’s net income was 24.8% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Caredx Inc
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CDNA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CDNA stock FAQ
What is CDNA stock’s price today?
Caredx (CDNA) traded at $64.00 at the close on , down $2.68 (4.01%) from the previous close of $66.68. Over the past 52 weeks it has traded between $14.03 and $72.51.
If you invested $1,000 in CDNA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CDNA on would be worth about $17,297 at the close on , a total return of +1,629.7%. The same $1,000 would be worth $901 if invested five years ago and $4,270 if invested one year ago. Past performance doesn’t predict future returns.
What is CDNA’s P/E ratio?
CDNA trades at 30.9 times its diluted earnings over the four quarters to ($2.07 per share), at the close. (How the P/E ratio works.)
How much revenue does Caredx make?
Caredx reported $458.1 million of revenue over the four quarters to , up 34.4% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $131.9 million, up 52.2% from a year earlier.
Is Caredx profitable?
Yes. Caredx earned $111.0 million of net income over the four quarters to , a net margin of 24.2%, and its operating margin was 23.6% (what margins tell you).
What are CDNA’s earnings per share?
CDNA’s diluted earnings per share were $2.07 over the four quarters to , compared with $1.05 in the twelve months before. The latest quarter (Q2 FY26) brought $2.07 per share, against −$0.16 a year earlier (how EPS works).
Does CDNA pay a dividend?
Caredx hasn’t paid a dividend in the last twelve months.
What is CDNA’s 52-week high and low?
Over the past 52 weeks CDNA has traded as low as $14.03 and as high as $72.51. At $64.00 at the close on , it is 11.7% below that high and 356.2% above the low.
What is CDNA’s all-time high?
CDNA’s highest closing price was $95.60 on , adjusted for stock splits. At $64.00 at the close on , it is 33.1% below that record.
Has CDNA stock ever split?
No. CDNA hasn’t split since its price history begins in 2014.
How has CDNA stock performed?
Including dividends and measured to the close on , CDNA has returned +239.7% so far this year and +327.0% over the past year, and −9.9% over five years (−2.1% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Caredx in?
Caredx is in the Healthcare sector and the Diagnostics & Research industry, and is headquartered in California, USA.
What exchange does CDNA trade on?
Caredx trades on the Nasdaq under the ticker symbol CDNA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.